Macquarie Group LTD Syndax Pharmaceuticals Inc Transaction History
Macquarie Group LTD
- $86.4 Billion
- Q4 2024
A detailed history of Macquarie Group LTD transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Macquarie Group LTD holds 180,000 shares of SNDX stock, worth $2.95 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
180,000
Previous 243,352
26.03%
Holding current value
$2.95 Million
Previous $4.68 Million
49.21%
% of portfolio
0.0%
Previous 0.01%
Shares
12 transactions
Others Institutions Holding SNDX
# of Institutions
232Shares Held
96.9MCall Options Held
1.39MPut Options Held
543K-
Kynam Capital Management, LP Princeton, NJ8.52MShares$140 Million7.14% of portfolio
-
Black Rock Inc. New York, NY7.91MShares$130 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY5.95MShares$97.5 Million0.01% of portfolio
-
Morgan Stanley New York, NY5.31MShares$87 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.88MShares$80 Million0.0% of portfolio
About Syndax Pharmaceuticals Inc
- Ticker SNDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,565,200
- Market Cap $927M
- Description
- Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...